CLINICAL TRIALS PROFILE FOR ESTRADIOL HEMIHYDRATE

All Clinical Trials for ESTRADIOL HEMIHYDRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00877097 ↗	Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women	Completed	Kuopio University Hospital	N/A	1996-07-01	Recent studies suggest that the combination of two inhibitors of bone resorption may induce a greater increase in bone mineral density (BMD) than either agent alone. In this 5-year partly randomized study the investigators examined the effects of hormone therapy (HT) with or without bisphosphonate on BMD on osteoporotic women. In the Kuopio Osteoporosis Study (OSTPRE) a population based sample of 3200 women were selected for BMD measurement by Lunar DPX in 1995-1997. In all 167 women aged 61±2.7 years (11±4.9 years postmenopausal), and the T-score < -2.5 SD at either the lumbar spine or femoral neck were recruited for this sub-study. They received daily estradiol hemihydrate (E2) 2mg + norethisterone acetate (NETA) 1mg (Kliogest®, Novo Nordisk, Denmark) and were randomized to get additional Boneplac, which consisted of either 800mg clodronate (Bonefos®, Leiras Ltd, Finland) (n=55, KB-group) or placebo (n=55, K-group). In case of contraindications or refusal from HT, the women were offered clodronate 800 mg/day (n=57, B-group) to be taken to empty stomach with a glass of water 30 minutes to two hours before breakfast. BMD was measured at time intervals 0, 1, 3 and 5-years. All repeated BMD values were interviewed by one investigator and primarily the vertebrae L2-L4 were followed. In case of spinal deformities during the study (38.3%) other lumbar levels were followed. The baseline BMD values (lumbar spine BMD 0.839±0.072 g/cm², femoral neck BMD 0.759±0.094g/cm²) were similar between the groups.
NCT00913926 ↗	Effects of Wellnara on Climacteric Symptoms	Completed	Bayer		2007-09-01	Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice. Furthermore, any adverse drug reactions will be recorded in a large user population under the conditions of medical routine. To investigate the efficacy of Wellnara, patients will fill in a questionnaire, the so-called Menopause Rating Scale (MRS II). Further, the effects of treatment on skin and hair will be evaluated by the investigator. Patients will assess treatment effects on their sexual life. Safety parameters include monitoring of vaginal bleeding, measurement of blood pressure and body weight, and - as far as routinely used in the practice - calculation of waist-hip-ratio. Any relevant additional information related to adverse drug reactions will also be documented.
NCT03077555 ↗	Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception	Completed	Mahidol University	Phase 4	2017-01-21	Quick starting combined oral contraception containing estradiol hemihydrate/nomegestrol acetate is effective to inhibit ovulation in healthy reproductive age women and non-inferiority to combined oral contraception containing ethinyl estradiol/gestodene.
NCT04021017 ↗	PRE-GAiN Bone Health Pilot Study	Recruiting	Jim Pattison Children's Hospital Foundation	Phase 1	2020-01-21	This study will assess the affects of an estradiol hemihydrate transdermal system on bone health in 24 adolescent females aged 12-19 years old with anorexia nervosa. Participants in this study will be randomized 1:1 into 2 groups. One group will receive treatment with a transdermal estrogen patch and the other group will not.
NCT04021017 ↗	PRE-GAiN Bone Health Pilot Study	Recruiting	University of Saskatchewan	Phase 1	2020-01-21	This study will assess the affects of an estradiol hemihydrate transdermal system on bone health in 24 adolescent females aged 12-19 years old with anorexia nervosa. Participants in this study will be randomized 1:1 into 2 groups. One group will receive treatment with a transdermal estrogen patch and the other group will not.
NCT06396390 ↗	Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes	NOT_YET_RECRUITING	Nesta Clinic	PHASE4	2024-08-01	The goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: Progestin Primed Ovarian Stimulation (PPOS) vs. GnRH Antagonist in embryologic outcomes of IVF Patients.
NCT06508944 ↗	Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women	COMPLETED	Mahidol University	PHASE4	2024-04-08	The goal of this clinical trial is to evaluate whether vaginal 17β-estradiol effectively treats storage symptoms of lower urinary tract symptoms (LUTS) and enhances quality of life. The main questions it aims to answer are: * What is the efficacy of vaginal 17β-estradiol treatment compared to placebo in alleviating storage symptoms of LUTS? * How does vaginal 17β-estradiol treatment affect the urethral maturation index and vaginal pH compared to placebo? * What impact does vaginal 17β-estradiol treatment have on overall quality of life and patients' perception of global improvement (PGI)? Participants in the trial will undergo the following procedures: * Screening procedures at the first visit to exclude correctable causes of LUTS and to complete a bladder diary. * Visit the clinic at 1-2 weeks for a review of the bladder diary and a check-up. Participants will receive the assigned dosage of vaginal 17β-estradiol or placebo: one vaginal tablet daily for two weeks, followed by one vaginal tablet twice a week for 10 weeks. * The third and fourth visits (at 4 and 12 weeks after treatment) will involve: completion of bladder diaries, questionnaires, vaginal pH testing, collection of urethral maturation index (UMI), observation of intervention's side effects and monitoring of LUTS symptoms.

Clinical Trial Conditions for ESTRADIOL HEMIHYDRATE

Condition Name

Condition Name for ESTRADIOL HEMIHYDRATE
Intervention	Trials
Overactive Bladder Syndrome	1
Bladder, Overactive	1
Ovulation Inhibition	1
Breast Cancer	1

Condition MeSH

Condition MeSH for ESTRADIOL HEMIHYDRATE
Intervention	Trials
Osteoporosis	1
Nocturia	1
Lower Urinary Tract Symptoms	1
Female Urogenital Diseases	1

Clinical Trial Locations for ESTRADIOL HEMIHYDRATE

Trials by Country

Trials by Country for ESTRADIOL HEMIHYDRATE
Location	Trials
Thailand	2
Germany	1
Turkey (Türkiye)	1
Canada	1
Finland	1

Clinical Trial Progress for ESTRADIOL HEMIHYDRATE

Clinical Trial Phase

Clinical Trial Phase for ESTRADIOL HEMIHYDRATE
Clinical Trial Phase	Trials
PHASE4	2
PHASE2	1
Phase 4	1

Clinical Trial Status

Clinical Trial Status for ESTRADIOL HEMIHYDRATE
Clinical Trial Phase	Trials
Completed	5
NOT_YET_RECRUITING	1
Recruiting	1

Clinical Trial Sponsors for ESTRADIOL HEMIHYDRATE

Sponsor Name

Sponsor Name for ESTRADIOL HEMIHYDRATE
Sponsor	Trials
Mahidol University	2
Kuopio University Hospital	1
Bayer	1

Sponsor Type

Sponsor Type for ESTRADIOL HEMIHYDRATE
Sponsor	Trials
Other	6
Industry	1
NETWORK	1

Estradiol Hemihydrate: Clinical Trial Update and Market Outlook

Last updated: May 2, 2026

What is the current clinical and development landscape for estradiol hemihydrate?

Estradiol hemihydrate is the solid-state form used in multiple estradiol hormone replacement and women’s health products, most notably transdermal systems and oral formulations where the active is labeled as estradiol hemihydrate. Across geographies, clinical activity is dominated by: (1) lifecycle studies for specific dosage forms and strengths, (2) bioequivalence and bridging work tied to regulatory submissions, and (3) label-expansion efforts in indications such as menopausal symptoms and vulvar and vaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM), depending on product.

Because estradiol is an established class drug, most “new” trial activity tied to “estradiol hemihydrate” typically reflects formulation lifecycle rather than first-in-class mechanism research. Trial programs are commonly powered for pharmacokinetic endpoints, safety/tolerability, and adherence-related outcomes rather than long-horizon comparative efficacy endpoints.

Clinical development signals (how programs usually show up)

For estradiol hemihydrate products, trial registries and regulatory dossiers generally map into three buckets:

1. Bridging/bioequivalence studies to support manufacturing changes, new strengths, or alternate delivery formats.
2. Safety and tolerability studies focused on menopause-related symptom endpoints and local tolerability for vaginal indications, if applicable to the product’s approved label.
3. Switching and adherence studies that evaluate real-world usability outcomes for patients and prescribers tied to a specific dosage form.

Where does “estradiol hemihydrate” sit in the competitive ecosystem?

Estradiol competes in a crowded market that spans multiple routes (oral, transdermal patches, gels/sprays, vaginal creams/tablets/rings). Market competition is driven by:

• route preference and patient adherence,
• safety navigation (endometrial protection needs with systemic estrogen in patients with an intact uterus),
• formulation reliability (dose delivery consistency, skin tolerability for transdermal products),
• and payer coverage.

Estradiol hemihydrate is typically not evaluated as a standalone differentiator in market perception; it is evaluated through the lens of the finished product (patch, gel, tablet, vaginal formulation) and its clinical label.

What market data supports a projection for estradiol hemihydrate?

A direct “estradiol hemihydrate-only” market sizing is rarely published as a standalone metric. The market is usually reported at the broader level of:

• estradiol drugs overall (by route),
• estrogen products for menopausal disorders,
• and GSM/VVA therapy markets.

Projection logic for investors and commercial planners therefore uses a route-mix model:

• Systemic menopausal symptom therapy remains the volume anchor for estradiol-containing regimens.
• VVA/GSM contributes incremental growth where vaginal/local products capture increased diagnosis and treatment adoption.
• Biosimilar/biologic competition is not the core threat because estradiol products are small-molecule hormones; the main erosion risks are generic penetration and lifecycle competition.

Market projection framework (route-mix with lifecycle and generic dynamics)

Use the following projection drivers for an estradiol hemihydrate product portfolio:

1. Aging demographics: steady tailwind for menopausal treatment demand.
2. Diagnosis and treatment rates: VVA/GSM screening and willingness to treat drive incremental volume.
3. Route preference: transdermal growth typically correlates with tolerability and clinician preference in certain populations; oral remains price-sensitive and competition-prone.
4. Generic intensity: erosive for branded pricing unless protected by formulation-specific IP, exclusivity, or differentiated dosing design.
5. Payer policy: step edits and formulary placement heavily determine realized demand for specific routes and brands.

How does IP likely affect market durability for estradiol hemihydrate products?

Estradiol itself has long-established patent expiry across most markets; product-level durability hinges on:

• formulation patents (e.g., specific transdermal design elements, controlled-release structures),
• manufacturing process claims,
• and method-of-use claims if pursued.

In practice, for estradiol hemihydrate products, commercial longevity tends to be less about the active ingredient and more about:

• the protected finished product package,
• patient adherence characteristics,
• and brand/payer contracting strategy after generic entries.

What do the latest trial patterns imply for near-term uptake?

Near-term commercial uptake is typically shaped by trial and regulatory timelines in three ways:

• Bioequivalence and manufacturing changes keep products available, preventing supply shocks and maintaining shelf stability for generics and brand extensions.
• Safety and tolerability studies reduce prescriber friction, especially where local tolerability matters (VVA/GSM) or where transdermal irritation risk is a key concern.
• Label bridging supports broader switching between strengths or dosage variants while maintaining reimbursement eligibility.

Clinical trials update: what is the actionable takeaway for R&D planning?

If you are evaluating investment or development in estradiol hemihydrate, the most actionable view is that “new evidence” in this space usually comes through:

• tighter pharmacokinetic and bioequivalence packages,
• improved usability endpoints,
• and label expansions rather than novel mechanism trials.

Commercially, that means success criteria often align to:

• dose consistency and patient adherence performance,
• local tolerability,
• and payer acceptance tied to finished product differentiation.

Market outlook and projection (3-scenario view)

Because standalone estradiol hemihydrate sizing is not typically disclosed, projections are best handled as scenarios for the finished-product category (systemic estrogen therapy and, separately, vaginal/local estrogen therapy where relevant).

Scenario assumptions

Driver	Base case	Upside	Downside
Demographic demand	steady growth from aging population	higher diagnosis/treatment uptake	slower diagnosis growth
Route mix	gradual shift toward favored routes (often transdermal/local)	faster route adoption	route shift stalls
Competition	continued generic erosion on branded pricing	differentiation holds in contracted channels	aggressive generic substitutions
IP/Exclusivity	limited but meaningful lifecycle protection for specific product variants	stronger formulation protection	earlier and deeper erosion

What to expect by horizon

• Near term (0-24 months): realized demand will track formulary placement, supply stability, and launch execution for the specific dosage form tied to estradiol hemihydrate.
• Mid term (2-5 years): category growth persists, but price per treatment declines where generics expand. Product winners hold share through patient adherence, prescriber preference, and localized label fit (systemic vs VVA/GSM).
• Longer term (5+ years): growth shifts toward diagnosis and persistence improvements rather than new molecular differentiation.

Key competitive benchmarks to anchor projections

To ground projection work to business metrics, track:

1. Route-level volumes (prescription counts by oral vs transdermal vs vaginal/local).
2. WAC vs net pricing (net erosion patterns post-generic).
3. Formulary position (preferred status changes and step-therapy implementation).
4. Persistence and adherence (especially transdermal and vaginal regimens where real-world discontinuation matters).
5. Adverse event profile in label updates (drives switching and persistence).

Key Takeaways

• Estradiol hemihydrate development is dominated by lifecycle and formulation-level studies, not mechanism novelty.
• Market upside comes primarily from demographic tailwinds and improved diagnosis/treatment persistence for menopausal disorders and GSM/VVA, with route mix and payer coverage determining realized performance.
• Generic competition drives price erosion; durable value is typically created through product-specific differentiation, label fit, and contracted formulary placement rather than active-ingredient exclusivity.

FAQs

1) Is “estradiol hemihydrate” itself a novel therapeutic class?

No. It is a solid-state form of estradiol used in marketed hormone replacement products. Clinical activity is usually lifecycle-oriented.

2) What trial endpoints typically matter most for estradiol hemihydrate programs?

For most lifecycle submissions, pharmacokinetics (bioequivalence), safety/tolerability, and adherence-related outcomes dominate over long-term comparative efficacy.

3) What is the main market risk for estradiol hemihydrate products?

Generic entry and payer-driven substitution that compresses net pricing, especially where differentiation is limited to strength or manufacturing changes.

4) Where does growth most likely come from: systemic or vaginal/local use?

Both can grow, but incremental adoption often comes from VVA/GSM diagnosis and treatment persistence for vaginal/local regimens, depending on the specific product’s approved indication.

5) What commercial lever most affects realized demand?

Formulary placement and net pricing under contracting conditions for the specific dosage form tied to estradiol hemihydrate.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Trials Snapshots. https://www.fda.gov/drugs/drug-trials-snapshots
[2] ClinicalTrials.gov. Search results for estradiol hemihydrate (accessed 2026-05-03). https://clinicaltrials.gov/
[3] World Health Organization (WHO). Menopause and associated health conditions: health topics (general background). https://www.who.int/health-topics/menopause